These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 856698)

  • 1. [Pharmacokinetics of cardiac glycosides and clinical consequences].
    Rietbrock N; Kuhlmann J; Vöhringer HF
    Fortschr Med; 1977 Apr; 95(14):909-15, 951-4. PubMed ID: 856698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of cardiac glycoside drug interactions.
    Hooymans PM; Merkus FW
    Clin Pharm; 1985; 4(4):404-13. PubMed ID: 2412751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digitalis therapy in renal failure with special regard to digitoxin.
    Vöhringer HF; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):175-84. PubMed ID: 7021432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effective concentration and dosage for cardiac glycosides].
    Weiss M; Förster W
    Z Gesamte Inn Med; 1980 Jan; 35(1):1-7. PubMed ID: 6996345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical significance of plasma glycoside concentrations in patients with cardiac pacemakers (author's transl)].
    Ochs HR; Bodem G; Schlehbusch H; Nuppeney M; Baur MP; Oberhoffer G
    Z Kardiol; 1978 Feb; 67(2):109-15. PubMed ID: 636517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digitalis pharmacokinetics and therapy with respect to impaired renal function.
    Kramer P
    Klin Wochenschr; 1977 Jan; 55(1):1-11. PubMed ID: 319291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Concentration of cardiac glycosides in the heart and brain (author's transl)].
    Flasch H; Heinz N
    Arzneimittelforschung; 1976; 26(6):1213-6. PubMed ID: 989419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of digoxin and methyldigoxin in patients with acute hepatitis (author's transl)].
    Zilly W; Richter E; Rietbrock N
    Med Klin; 1978 Mar; 73(13):463-9. PubMed ID: 634206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The past and the present of cardiac glycosides. III. Pharmacokinetics].
    Synek P
    Cas Lek Cesk; 1991 Feb; 130(5):148-51. PubMed ID: 2004406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency].
    Rietbrock N; Woodcock BG; Hrazdil U
    Arzneimittelforschung; 1984; 34(8):915-7. PubMed ID: 6541927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides.
    Smith TW
    J Am Coll Cardiol; 1985 May; 5(5 Suppl A):43A-50A. PubMed ID: 3921586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of meproscillarin rates of inactivation and persistence, bioavailability and maintenance dose].
    Herken H; Brandes J
    Arzneimittelforschung; 1978; 28(3a):557-60. PubMed ID: 580590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the possible meproscillarin accumulation in patients with impaired renal function (author's transl)].
    Twittenhoff WD; Brittinger WD; Deckert DW; Belz GG; Schubert I
    Arzneimittelforschung; 1978; 28(3a):562-5. PubMed ID: 580591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic equivalence and inequivalence of chemically identical substances using cardiac glycosides for an example (author's transpl)].
    Rietbrock N
    Arzneimittelforschung; 1976; 26(1A):135-46. PubMed ID: 947193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum half-life and renal clearance of 3H peruvoside. Study on normal persons and patients with terminal kidney insufficiency].
    Kramer P; Willms B; Horenkamp J; Scheler F
    Verh Dtsch Ges Kreislaufforsch; 1969; 35():440-4. PubMed ID: 5380625
    [No Abstract]   [Full Text] [Related]  

  • 16. [Indications, contra-indications and dosage of cardiac glycosides controlled by plasma levels in the aged].
    Hötter GJ
    Z Gerontol; 1987; 20(1):8-12. PubMed ID: 3577317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on cardioactive steroids. III. Characterization of different cardiac glycosides by their effects on contractility and rhythmicity at different extracellular potassium concentrations.
    Haustein KO; Graumann G; Stephan B
    Acta Biol Med Ger; 1975; 34(6):1065-73. PubMed ID: 1199622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individual glycoside therapy using serum concentration determination in canine heart failure].
    Staudacher G
    Dtsch Tierarztl Wochenschr; 1989 May; 96(6):308-10. PubMed ID: 2758985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimization of therapy using cardiac glycosides].
    Ziesenhenn K; Behn P
    Z Gesamte Inn Med; 1978 Nov; 33(22):830-3. PubMed ID: 746673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy.
    Kuhlmann J
    Arzneimittelforschung; 1982; 32(6):698-704. PubMed ID: 6889430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.